ASSOCIATION OF BLOOD INFLAMMATORY MARKERS WITH ANKLE BRACHIAL PRESSURE INDEX IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Rama Prakasha S*, Rakshatha Nayak, Suchetha Kumari N, Ganesh Kumar S

*K. S. Hegde Medical Academy, Deralakatte, Mangalore, Karnataka, India.

*Corresponding Author: dr_prakashbhat@yahoo.co.in

This article is available online at www.ssjournals.com

ABSTRACT

Background: A significant positive correlation exists between the inflammatory markers, hs-CRP (C reactive protein) and ferritin and the parameters of dyslipidemia in patients with type 2 diabetes. Not much is known regarding diabetes, inflammation and vasculopathy especially in relation to ferritin from this region. Aim: To correlate serum CRP and ferritin levels with Ankle Brachial Pressure Index (ABPI) in type 2 diabetic patients. Methodology: Descriptive observational study of 50 diabetic patients done at K. S. Hegde Medical College Hospital, Mangalore, Karnataka, India. Results: ABPI correlated negatively with serum ferritin values; with a Pearson correlation value and p value of -0.187 and 0.194 respectively. Also, ABPI negatively correlated with CRP, and this correlation was statistically significant (-0.382, P=0.006). Conclusion: Measurement of ABPI is a simple and clinically useful tool in identifying peripheral arterial disease in patients at risk of accelerated atherosclerosis. ABPI negatively correlated with serum ferritin and CRP levels in this study, though the association with ferritin was statistically not significant. Further large scale studies are needed to elucidate the association of ferritin as a nonconventional risk factor of atherosclerosis and PAD in type 2 diabetes mellitus. Keywords: Ankle Brachial Pressure Index (ABPI), hs-CRP (C reactive protein), Ferritin, Type 2 Diabetes mellitus, Cardio-Vascular Disease (CVD), Inflammation

1. Introduction

Atherosclerosis is a chronic low-grade inflammatory disease. A significant positive correlation exists between the inflammatory markers, hs-CRP (C reactive protein) and ferritin and the parameters of dyslipidemia in patients with type 2 diabetes. Serum C-reactive protein (CRP) has proven to be an independent marker of the extent of atherosclerosis in patients with coronary, cerebrovascular and peripheral arterial disease. Also, elevated circulating ferritin concentrations were associated with higher risk of type 2 diabetes and metabolic syndrome in middle-aged and elderly patients independent of obesity, inflammation and other risk factors. Comparison of BP measurements in the ankle and arm is a simple, low-cost diagnostic test for the detection of PVD. The ABI, a ratio of the ankle and arm pressures (also referred to as ankle/arm index [AAI] and ABPI) has been used widely in clinical and epidemiological studies to screen for PAD and is believed to be highly correlated with the PAD of lower extremity. An ABPI value less than 0.9 is an independent risk factor for an episode of CVD, for recurrent CVD and for mortality in elderly adults. Studies have shown the sensitivity of ABPI to be 90% with a corresponding 98% specificity for detecting hemodynamically significant stenosis >50% in major leg arteries, defined by angiogram. Correlations between levels of ferritin, inflammatory biomarkers, and mortality in patients with peripheral arterial disease (PAD) is also described previously, but, not much is known regarding diabetes, inflammation and vasculopathy especially in relation to ferritin from this region. With this in the background, the study was done to correlate serum CRP and ferritin levels with ABPI in type 2 diabetic patients.

2. Materials and Methods

2.1 Study group: The study was done at K.S.Hegde Medical College Hospital, Deralakatte, Mangalore, Karnataka, India. This was an observational and analytical study of 50 patients with type 2 diabetes mellitus done during the period of June 2011 to August 2011. Study protocol was explained to the study population and consent was taken. The institutional ethical committee clearance was taken before the study. Study population was divided into group 1 with CVD and group 2 without CVD. All patients who fulfilled the
following inclusion criteria were considered for study.

**Inclusion criteria:**
1. Patients with Type 2 diabetes with the diagnosis of diabetes as per WHO criteria
2. No episode of ketoacidosis
3. Diagnosis of diabetes after the age of 30 years
4. Insulin therapy, if any, started after at least 5 years of known disease

**Exclusion Criteria**
1. Smoking
2. Renal failure with a serum creatinine concentration over 1.5 mg/dL
3. Age more than 60 years
4. Anemia with haemoglobin of ≤ 11 gms/dl.
5. Patients with liver disease (viral hepatitis or liver cirrhosis), known malignant disease, acute infections or chronic inflammatory disease (e.g., rheumatoid arthritis)

**2.2 Definitions and diagnostic criteria:**
Diabetes was diagnosed based on past medical history, drug treatment for diabetes (insulin or oral hypoglycemic agents) and/or criteria outlined by the World Health Organization. Diabetes was diagnosed if fasting plasma glucose (FPG) level was > 126 mg/dl and/or the 2-hr plasma glucose level was > 200 mg/dl.

Hypertension was diagnosed based on the history of drug treatment for hypertension or if blood pressure was > 140/90 mmHg.

Hypercholesterolemia and hypertriglyceridemia were defined as serum cholesterol or triglycerides were > 200 mg/dl and > 130 mg/dl, respectively, according to the National Cholesterol Education Program guidelines.

CVD was defined as coronary artery disease and/or stroke and/or PVD. Coronary artery disease is defined as a history of myocardial infarction, coronary artery bypass grafting or an abnormal coronary angiogram. Stroke is defined as a history of ischemic stroke confirmed by cerebral computed tomography or nuclear magnetic resonance imaging. PVD is defined as symptoms of intermittent claudication or a documented PVD by arterial doppler or peripheral angiogram respectively. The mean diabetes duration was 7.38 ± 6.91 years. The mean BMI (kg/m²) and waist-to-hip ratio were 21.91 ± 3.70 and 0.97 ± 0.06 respectively. The mean serum cholesterol and triglycerides were 173.68 ± 33.36 mg/dl and 129.54 ± 41.24 mg/dl respectively. The mean LDL (mg/dl) and HDL (mg/dl) were 105.6 ± 31.74 and 42.12 ± 6.99 respectively. The mean ABPI was 0.99 ± 0.22 in the study group. The mean ferritin was 303.07 ± 175.22 mg/dl and the mean CRP (mg/dl) was 5.70 ± 1.82 in the study group.

**3. Results**
In this study of 50 patients with type 2 diabetes mellitus in the age group of 30-60 years, 35(70%) were males and 15(30%) were females. The mean age was 52.36 years and majority of them (40, 80%) belonged to the age group of 51-60 years. 10 cases (20%) had past history of MI or CAD. 20 cases (40%) had PVD as defined above. Among them, 6 cases and 2 cases had documented PVD by arterial doppler or peripheral angiogram respectively. The mean BMI (kg/m²) and waist-to-hip ratio were 21.91 ± 3.70 and 0.97 ± 0.06 respectively. The mean serum cholesterol and triglycerides were 173.68 ± 33.36 mg/dl and 129.54 ± 41.24 mg/dl respectively. The mean LDL (mg/dl) and HDL (mg/dl) were 105.6 ± 31.74 and 42.12 ± 6.99 respectively. The mean ABPI was 0.99 ± 0.22 in the study group. The mean ferritin was 303.07 ± 175.22 mg/dl and the mean CRP (mg/dl) was 5.70 ± 1.82 in the study group.

**2.4 Measurement of Ankle-brachial Pressure Index:**
Blood pressure recordings were made of the brachial pulses in the both upper limb. Similar recordings were made of the dorsalis pedis and posterior tibial pulses in the both lower limb by inflating the cuff proximal to the ankle, and the mean of these 2 readings was taken as the ankle pressure. ABPI is calculated using the formula:

$$\text{ABPI}_{\text{Leg}} = \frac{P_{\text{Leg}}}{P_{\text{Arm}}}$$

Where $P_{\text{Leg}}$ is the systolic blood pressure of dorsalis pedis or posterior tibial arteries and $P_{\text{Arm}}$ is the highest of the left and right arm brachial systolic blood pressure.

**Statistical analysis:** Data was expressed as the mean ±SD. Differences between groups will be analyzed by a Student’s unpaired t test. Correlation was determined by Pearson correlate test. A p value of 0.05 was accepted as indicating statistical significance.
Among 15 females, 7 (46.67%) were in the group with CVD and 8 (53.33%) were in the group without CVD. The cases were grouped into four groups depending on the ABPI values as 0.40–0.69, 0.70–0.90, 0.91–1.30 and >1.30. The numbers of cases in each group were 4, 17, 27 and 2 respectively. The two groups with and without CVD were compared for the baseline characteristics. The mean age of diabetic patients with and without CVD was 54.44 ± 3.86 and 50.28 ± 9.59 years respectively (p = 0.019). The mean diabetes duration in the two groups was 7.80 ± 4.33 and 6.96 ± 8.86 years respectively. The BMI (Kg/m²) and waist to hip ratio in the two groups were 22.58 ± 3.90 vs. 21.23 ± 3.44 and 0.97 ± 0.66 vs. 0.96 ± 0.05 respectively. The serum LDL (mg/dl) in the group with CVD was higher than the group without CVD (121.32 ± 35.97 vs. 89.88 ± 15.76) with a p value of 0.08. The serum triglyceride (mg/dl) in the group with CVD was higher than the group without CVD (156.16 ± 40.68 vs. 102.92 ± 17.93) and this difference was statistically significant (p 0.01). The mean ABPI in the group with CVD and without CVD was 0.84 ± 0.14 and 1.15 ± 0.18 respectively. The serum ferritin (mg/dl) and CRP (mg/dl) in the group with CVD were higher than in the group without CVD (393.44 ± 179.11 vs. 212.70 ± 116.58 and 6.47 ± 1.79 vs. 4.93 ± 1.53). 

4. Discussion

The main observations of the present study are the following: 35 cases (70%) were males and majority of the cases (40, 80%) belonged to the age group of 51-60 years. CVD was also more common in the age group of 51-60 years (17 cases, 68%). Also, males contributed to more number of cases with low ABPI than females. Among the cases with ABPI of < 0.9 (21 cases), 15 were males and 6 were females. Both the groups with CVD and without CVD were matched with respect to diabetes duration, BMI, waist to hip ratio and serum cholesterol levels. The mean age of diabetic patients with and without CVD was 54.44 ± 3.86 and 50.28 ± 9.59 years and this difference between two groups was statistically significant (p = 0.019). The mean ABPI was much lower in the group with CVD when compared with the group without CVD, though statistically not significant (p=0.701). The mean ferritin values (mg/dl) in the two groups were 393.44 ± 179.11 and 212.70 ± 116.58 respectively with a p value of 0.106. Also, CRP values (mg/dl) were much higher in the group with CVD than the group without CVD (6.47 ± 1.79 vs. 4.93 ± 1.53).

The risk factors for PAD in the general population have been well characterized. The Framingham Study and other studies have identified a number of atherogenic risk factors, including increasing age, male gender, hypertension, diabetes mellitus, smoking, and elevated serum cholesterol levels. More recently, several emerging unconventional risk factors such as homocysteine, lipoprotein (a) and chronic inflammation have been identified as additional risk factors associated with PAD. Accumulating evidence suggest that chronic inflammation plays a role in atherogenesis and several studies have demonstrated that elevated levels of CRP predicts an increased incidence of PAD in the general population. The ABPI values were compared in the group with and without CVD after dividing the cases into four groups according to ABPI. The difference in the ABPI between these two groups was statistically significant with a p value of <0.001. This highlights the importance of ABPI measurement in individuals with potential risk factors for CVD as well as established CVD cases to prevent further complications by taking appropriate therapeutic measures. The ABPI offers a potentially important low-cost, noninvasive tool for the early assessment of generalized atherosclerotic disease as well as for PVD specifically. PAD as measured by the ankle/brachial blood pressure index (ABPI) is associated with the increased risk of mortality and morbidity in several patient populations. In this study, ABPI correlated negatively with serum ferritin values, with a Pearson correlation value and p value of -0.187 and 0.194 respectively. Also, ABPI negatively correlated with CRP, and this correlation was statistically significant (-0.382; P=.006). Though the small sample size is a limitation in this study, measurement of ABPI as a simple tool may be clinically useful in identifying peripheral arterial disease in patients at risk of accelerated atherosclerosis. To conclude, ABPI negatively correlated with serum ferritin and CRP levels in this study, though the association with ferritin was statistically not significant. Further large scale studies are needed to
elucidate the association of ferritin as a nonconventional risk factor of atherosclerosis and PAD in type 2 diabetes mellitus.

References
1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340:115–26.
2. Waheed P, Naveed AK, Farooq F. Levels of inflammatory markers and their correlation with dyslipidemia. J Coll Physicians Surg Pak 2009; 19:207-10.
3. Liang Sun, Oscar H Franco, Frank B Hu, Lu Cai, Zhijie Yu, Huaxing Li, et al. Ferritin Concentrations, Metabolic Syndrome. J Clin Endocrinol Metab 2008; 93:4690 -96.
4. Orchard TJ, Strandness DE. Assessment of peripheral vascular disease in diabetes: report and recommendations of an international workshop sponsored by the American Diabetes Association and the American Heart Association. Circulation 1993; 88:819-28.
5. Smith FB, Lee AJ, Price JF, van Wijk MC, Fowkes FG. Changes in ankle brachial index in symptomatic and asymptomatic subjects in the general population. J Vasc Surg 2003; 38:1323-30.
6. McDermott: ABI as a predictor of outcomes in PVD. J Lab Clin Med 1999; 133:33–40.
7. McDermott MM, Criqui MH, Liu K, Guralnik JM, Greenland P, Martin GJ, et al. "Lower ABI and association with leg functioning in PVD". J Vasc Surg 2000; 32:1164–71.
8. Depalma RG, Hayes VW, Chow BK, Shamayeva G, May PE, Zacharski LR. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial. J Vasc Surg 2010; 51:1498-503.
9. Tseng CH. Prevalence and risk factors of peripheral arterial obstructive disease in Taiwanese type 2 diabetic patients. Angiology 2000; 54:331-8.
10. Premalatha G, Shanthirani S, Deepa R, Markovitz J, Mohan V. Prevalence and Risk Factors of Peripheral Vascular Disease in a Selected South Indian Population-The Chennai Urban Population Study (CUPS). Diabetes Care 2000; 23:1295-300.
11. Kweon SS, Shin MH, Park KS, Nam HS, Jeong SK, Ryu SY, et al. Distribution of the Ankle-Brachial Index and Associated Cardiovascular Risk Factors in a Population of Middle-Aged and Elderly Koreans. J Korean Med Sci 2005; 20:373-8.
12. Cui R, Iso H, Yamagishi K, et al. Ankle-arm blood pressure index and cardiovascular risk factors in elderly Japanese men. Hypertens Res 2003; 26:377-82.
13. Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilaon PW. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002; 143:961-5.
14. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285:2481-5.
15. Hozawa A, Ohmori K, Kurimaya S. C-Reactive Protein and Peripheral Artery Disease among Japanese Elderly: the Tsurugaya Project. Hypertens Res 2004; 27:955-61.
16. Newman AB, Shemanski L, Manolio TA, Cushman M, Krotkiewski M, Polak JF, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in Cardiovascular Health Study. Arterioscler Thromb. Vasc Biol 1999; 19:538-45.
17. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996; 25:1172-81.

Table 1. Baseline characteristics of the study population (N=50)

|                           | Mean       |
|---------------------------|------------|
| Male/Female               | 35 (70%)/15(30%) |
| Age (years)               | 52.36 ± 7.54 |
| MI/CAD                    | 10 (20%)   |
| Stroke                    | 4 (8%)     |
| PAD                       | 20 (40%)   |
| Diabetes duration(years)  | 7.38 ± 6.91 |
| BMI (kg/m2)               | 21.91 ± 3.70 |
| Waist-to-hip ratio        | .97 ± .06  |
| Serum cholesterol (mg/dl) | 173.68 ± 33.36 |
| LDL                       | 105.6 ± 31.74 |
| HDL                       | 42.12 ± 6.99 |
| Serum triglycerides (mg/dl)| 129.54 ± 41.24 |
| Serum creatinine (mg/dl)  | .93 ± .26  |
| FPG                       | 183.82 ± 46.44 |
| Glyco-Hb                  | 8.32 ± 1.53 |
| ABPI                      | .99 ± .22  |
| Ferritin                  | 303.07 ± 175.22 |
| CRP                       | 5.70 ± 1.82 |
Table 2. Comparison of base line characteristics in the group with CVD and without CVD

|                          | With CVD (N=25) | Without CVD (N=25) | F value, P value |
|--------------------------|-----------------|--------------------|-----------------|
| Male/Female              | 17/8            | 18/7               |                 |
| Age (years)              | 54.44 ± 3.86    | 50.28 ± 9.59       | 5.846, 0.019*   |
| MI/CAD                   |                 | 10 (20%)           |                 |
| Stroke                   |                 | 4 (8%)             |                 |
| PAD                      |                 | 20 (40%)           |                 |
| Diabetes duration(years) | 7.80 ± 4.33     | 6.96 ± 8.86        | 0.435           |
| BMI (kg/m2)              | 22.58 ± 3.90    | 21.23 ± 3.44       | 0.368           |
| Waist-to-hip ratio       | 0.97 ± 0.66     | 0.96 ± 0.05        | 0.633           |
| Serum cholesterol (mg/dl)| 191.6 ± 30.8    | 155.76 ± 25.57     | 0.701           |
| LDL                      | 121.32 ± 35.97  | 89.88 ± 15.76      | 0.08            |
| HDL                      | 38.48 ± 5.51    | 45.76 ± 6.46       | 0.350           |
| Serum triglycerides (mg/dl)| 156.16 ± 40.68 | 102.92 ± 17.93     | 0.01*           |
| Serum creatinine (mg/dl) | 0.91 ± 0.29     | 0.95 ± 0.22        | 0.063           |
| FPG                      | 172.4 ± 46.51   | 195.24 ± 44.37     | 0.667           |
| Glyco-Hb                 | 8.18 ± 1.30     | 8.45 ± 1.74        | 0.572           |
| ABPI                     | 0.84 ± 0.14     | 1.15 ± 0.18        | 0.701           |
| Ferritin                 | 393.44 ± 179.11 | 212.70 ± 116.58    | 0.106           |
| CRP                      | 6.47 ± 1.79     | 4.93 ± 1.53        | 0.454           |

Table 3. Correlation of serum ferritin and CRP with ABPI (N=50)

| ABPI (Mean ± SD) | Ferritin (Mean ± SD) | CRP (Mean ± SD) | Pearson correlation (ABPI vs. ferritin)(P value) | Pearson correlation (ABPI vs. CRP) |
|------------------|----------------------|-----------------|-------------------------------------------------|-----------------------------------|
| 0.9943 ± .22194 | 303.07 ± 175.22      | 5.6985 ± 1.81773| -0.187 (0.194)                                  | -0.382 (0.006)                    |